Dr. Hariri pioneered the use of stem cells to treat a range of life-threatening human diseases and continues today to make transformative contributions in the fields of immuno-oncology and cell therapeutics along with tissue engineering and functional regeneration. He is widely acknowledged for his discovery of pluripotent stem cells derived from the human placenta, and as a member of the team that discovered the physiological activities of tumor necrosis factor (TNF). He holds over 170 issued and pending patents for discoveries including placenta-derived stem cells, which Nature recognized as one of the ten most important patent estates in the field. He has authored over 150 published chapters, articles, and abstracts.
Dr. Hariri was the founder and CEO of Anthrogenesis Corporation, and after its acquisition by Celgene Corporation, served as CEO of Celgene Cellular Therapeutics which was spun-out in 2017 to form Celularity. Dr. Hariri also co-founded the genomic-based health intelligence company, Human Longevity, Inc. and serves on numerous public boards including Cryoport (NASDAQ:CYRX).
Dr. Hariri is an Adjunct Professor of Neurosurgery and member of the Board of Overseers of the Weill Cornell Medical College and a former member of the board of visitors of the Columbia University School of Engineering and Applied Sciences, and the Science & Technology Council of the College of Physicians and Surgeons.
Dr. Hariri completed his undergraduate training at Columbia University School of Engineering and Applied Sciences and Columbia College. He received his M.D. and Ph.D. degrees from Cornell University, where he was the recipient of both the Julian R. Rachele Award and the Doctoral Dissertation Award. He was a surgical resident and fellow in neurosurgery at The New York Hospital-Cornell Medical Center and served as an Assistant Professor of Neurosurgery and Associate Research Professor of Surgery at Cornell and Co-director of the Aitken Laboratory in Neurosurgery.